Xi'an Janssen President Asgar reappointed as rdpac Chairman

On November 21, rdpac of China Association of foreign funded enterprises announced the new executive committee's leadership list As a trusted partner of the Chinese government, rdpac has been committed to supporting China to build a high-level open economy, enhance its pharmaceutical innovation capacity and improve the well-being of patients for 20 years I am confident that I will continue to lead rdpac and all member companies to continue to improve China's pharmaceutical innovation ecosystem, fulfill the promise of benefiting more Chinese and global patients, and help to achieve the 2030 goal of healthy China! " ——In recent years, thanks to favorable policies, China's pharmaceutical innovation pattern is developing rapidly Rdpac will continue to focus on the industry consensus, continue to consolidate the cornerstone of sustainable development of pharmaceutical innovation ecosystem, and help the government to continuously optimize the business environment and policy environment for pharmaceutical innovation Rdpac is a non-profit organization composed of 42 multinational pharmaceutical enterprises with research and development capabilities, which is affiliated to the "China Association of foreign invested enterprises" At present, rdpac member companies have set up 49 production plants and 31 R & D centers in China, with an annual R & D investment of about 8 billion yuan Rdpac continues to provide high-quality and innovative medical and health products and services for Chinese patients, supports China to establish an innovative ecosystem for sustainable development, and is committed to becoming an important partner for China to achieve the 2030 goal of healthy China and continuously improve the quality of life of residents and patients 37